Barclays PLC Acquires 245,909 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Barclays PLC boosted its position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 106.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 476,974 shares of the medical device company's stock after buying an additional 245,909 shares during the quarter. Barclays PLC owned approximately 0.73% of Tandem Diabetes Care worth $17,180,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. JPMorgan Chase & Co. raised its position in shares of Tandem Diabetes Care by 134.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company's stock valued at $8,379,000 after acquiring an additional 113,355 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in Tandem Diabetes Care by 163.4% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after purchasing an additional 1,101 shares during the period. US Bancorp DE grew its stake in Tandem Diabetes Care by 15.2% during the 4th quarter. US Bancorp DE now owns 38,708 shares of the medical device company's stock worth $1,394,000 after buying an additional 5,108 shares during the last quarter. KBC Group NV increased its position in Tandem Diabetes Care by 41.5% in the fourth quarter. KBC Group NV now owns 192,479 shares of the medical device company's stock worth $6,933,000 after buying an additional 56,461 shares during the period. Finally, Envestnet Portfolio Solutions Inc. lifted its stake in Tandem Diabetes Care by 22.0% in the fourth quarter. Envestnet Portfolio Solutions Inc. now owns 6,560 shares of the medical device company's stock valued at $236,000 after buying an additional 1,184 shares during the last quarter.

Tandem Diabetes Care Trading Up 0.6 %

NASDAQ TNDM traded up $0.10 on Friday, hitting $17.77. 227,127 shares of the company were exchanged, compared to its average volume of 1,498,684. Tandem Diabetes Care, Inc. has a twelve month low of $15.75 and a twelve month high of $53.69. The company's 50 day moving average price is $20.46 and its 200-day moving average price is $29.44. The firm has a market capitalization of $1.18 billion, a P/E ratio of -9.21 and a beta of 1.52. The company has a debt-to-equity ratio of 1.29, a current ratio of 2.90 and a quick ratio of 2.32.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on TNDM. Canaccord Genuity Group reiterated a "buy" rating and issued a $63.00 price objective on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. Morgan Stanley downgraded Tandem Diabetes Care from an "overweight" rating to an "equal weight" rating and reduced their price objective for the stock from $45.00 to $22.00 in a research report on Wednesday, March 5th. Wells Fargo & Company restated an "equal weight" rating and issued a $22.00 target price (down from $38.00) on shares of Tandem Diabetes Care in a research report on Monday, March 3rd. Barclays reduced their price target on Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Finally, Sanford C. Bernstein lowered Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $35.00 to $25.00 in a report on Friday, February 28th. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, Tandem Diabetes Care currently has a consensus rating of "Moderate Buy" and an average target price of $43.88.

Insider Activity

In other Tandem Diabetes Care news, COO Jean-Claude Kyrillos purchased 10,538 shares of the company's stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average cost of $18.12 per share, with a total value of $190,948.56. Following the completion of the transaction, the chief operating officer now owns 10,538 shares of the company's stock, valued at approximately $190,948.56. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 2.20% of the stock is owned by company insiders.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.